Agomab – tackling fibrosis through growth factors
Agomab is a biotech company developing novel treatments that aim to preserve and restore organ function in fibrotic diseases. By translating a deep expertise in growth factor biology, we pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure, and restore organ function. We combine our innovative R&D approach with an ambitious corporate strategy to develop a broad clinical pipeline of assets that target two key signaling pathways that are involved in fibrosis: transforming growth factor beta (TGFβ) and hepatocyte growth factor (HGF).
“WE ARE DETERMINED TO IMPROVE THE LIVES OF PATIENTS WITH FIBROTIC DISEASES. WE ARE BUILDING A LEADING COMPANY THAT COMBINES TRANSFORMATIVE SCIENCE WITH THE COMMITMENT AND PASSION OF OUR EXPERIENCED TEAM, PARTNERS, AND INVESTORS.”
Tim Knotnerus, Chief Executive Officer
Chief Executive Officer
Chief Medical Officer
Chief Development Officer
Chief Financial Officer
Chief Financial & Business Officer
General Counsel
Chairman of the Board
Independent Board member
Representing EQT Life Sciences
Representing Redmile
Representing Pontifax
Chief Executive Officer
PHARMA COMPANIES
Investment funds
The Agomab team has built a strong scientific foundation in targeting growth factors and modulating related molecular pathways through novel monoclonal antibodies and small molecule compounds to resolve fibrosis, regenerate tissue and restore organ functionality. We are working with leading academic institutions and industrial partners to develop treatment options for patients.
**The Secretary of State for Research, Development and Innovation and the Presidency of the State Research Agency has funded in the form of a loan the Project Origo GI “Discovery and development of new Immuno-Oncological and anti-fibrotic treatments with local effect – File: RTC2019-007449-1” in the 2019 call for R&D Projects « Challenges -Collaboration» of the State Program for Research, Development and Innovation Oriented to the Challenges of Society, within the framework of the State Research Plan Scientific and Technical and Innovation 2017-2020.